Funari appointment helms Imagia Canexia Health with a distinguished biology and data science leader to further the company’s precision cancer care mission.

Imagia Canexia Health, a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, today announced Vincent Funari Ph.D. as the company’s new Chief Science Officer (CSO). Vincent will apply his two-decades worth of unique proficiency—leading the intersection of molecular biology and advanced data science technology—to deliver precision cancer treatments for patients no matter where they live.

Throughout his career, he co-authored more than 45 peer-reviewed genomics papers in publications including: Nature Immunology, JAMA, Science, Nature Genetics, AJHG, and Genomics. Vincent joins ICH to realize their vision to combine advanced genomics, oncology, artificial intelligence, and informatics so health systems can provide cost-effective cancer testing in-house.

I’ve spent my entire career leveraging technology to create the biggest changes in bioinformatics, and it’s with great pleasure that I bring this experience to Imagia Canexia Health as the company’s Chief Science Officer,” said Vincent Funari, Ph.D. “Cancer remains one of the biggest battle grounds of our time, and leading ICH’s scientific efforts to provide treatment-testing for more people is incredibly motivating.

Vincent brings an unprecedented level of institutional knowledge to Imagia Canexia Health, especially his influential work at the intersection of science and technology,” said Imagia Canexia Health CEO Geralyn Ochab. “As we continue to close the health equity gap through data-driven cancer care, it’s with great confidence that we have Vincent leading our scientific strategy.

About Imagia Canexia Health
Imagia Canexia Health (ICH) is a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions. Leveraging AI-based informatics for treatment selection and monitoring, oncologists now have leading clinical decision support right at their fingertips. With a network of over 20 hospitals and reference labs worldwide, ICH ensures that doctors have the right insights to deliver cost-effective cancer testing to patients no matter where they seek treatment. Join ICH in closing the health-equity gap in cancer: imagiacanexiahealth.com

Contact:
Peter Weltman
peter@mow.media
(415) 340-2040‬

Back

Recent Resources

Blog

August 30, 2022

CGC 2022 Key Takeaways

NGS Reporting, Whole Genome Sequencing, and In-House Testing major themes in this year’s meeting